CADL
Candel Therapeutics, Inc.
$8.56
+4.90%
$627.2M
No data for this timeframe.
Vol
Market Cap$627.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (87%)
Inst. Holders50 funds
Inst. Value$132.1M
Inst. Activity7 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$3.0M
Reddit Sentiment62° Warm
SEC Reports3
Press Releases6
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001841387·Prev Close $8.16
Recent Activity
Jun 2, 2026
Press
Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized
Impact 8/10
Jun 2, 2026
fda
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
<p align="justify">NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Ca
May 15, 2026
Press
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-2409) in localized pro
Impact 8/10
May 14, 2026
SEC
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, driven by higher R&D
8-K — Impact 4/10
May 14, 2026
SEC
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi
PRESS-RELEASE — Impact 5/10
Mar 31, 2026
Insider
Manning Paul B was granted 4,618 shares
Director @ $4.11 ($19.0K)
Mar 31, 2026
Insider
PAPA JOSEPH C was granted 2,795 shares
Director @ $4.11 ($11.5K)
Mar 31, 2026
Insider
Loggia Nicoletta was granted 779 shares
Director @ $4.11 ($3.2K)
Price Targets
$20.29
+137.0% upside
Strong Buy
Current $8.56
Low $9.00
Median $23.00
High $29.00
7 analysts
$9.00
$29.00
Analyst Ratings
4Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 20, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 18, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.26 | $-0.26 — $-0.26 | -27% YoY | 1 |
| Next Q | $-0.26 | $-0.26 — $-0.26 | -15% YoY | 1 |
| Current FY | $-0.87 ▼ -13.4% | $-1.11 — $-0.74 | 0% YoY | 3 |
| Next FY | $0.22 ▲ +134.4% | $0.22 — $0.22 | 125% YoY | 1 |
Latest Reports
BULLISH
Press
8/10
Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized
Jun 2, 2026
NEUTRAL
8-K
4/10
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, driven by higher R&D
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no revenue. The company hi
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $53.8M | ADD |
| RTW INVESTMENTS, LP | $31.5M | NEW |
| BlackRock, Inc. | $15.2M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.1M | — |
| STATE STREET CORP | $4.0M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Manning Paul | A | $19.0K |
| Mar 31, 2026 | PAPA JOSEPH | A | $11.5K |
| Mar 31, 2026 | Loggia Nicoletta | A | $3.2K |
| Feb 23, 2026 | Manning Paul | BUY | $3.0M |
Reddit Sentiment
62°▼
Warm
Bearish
Neutral
Bullish
50 institutional holders with $132.1M total value (26,948,962 shares) as of 2026-Q1. Top holders: FMR, RTW, BlackRock,. Net buying activity: 7 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 10,987,017 | $53.8M | 40.8% | ADD +33.4% |
| 2 | RTW INVESTMENTS, LP | 6,422,018 | $31.5M | 23.8% | NEW |
| 3 | BlackRock, Inc. | 3,109,042 | $15.2M | 11.5% | ADD +49.0% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2,462,757 | $12.1M | 9.1% | — |
| 5 | STATE STREET CORP | 818,558 | $4.0M | 3.0% | — |
| 6 | VANGUARD FIDUCIARY TRUST CO | 280,451 | $1.4M | 1.0% | — |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 268,249 | $1.3M | 1.0% | — |
| 8 | GOLDMAN SACHS GROUP INC | 227,521 | $1.1M | 0.8% | — |
| 9 | ExodusPoint Capital Management, LP | 227,468 | $1.1M | 0.8% | — |
| 10 | JANUS HENDERSON GROUP PLC | 171,978 | $845.3K | 0.6% | — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 166,100 | $813.9K | 0.6% | — |
| 12 | Woodline Partners LP | 156,700 | $767.8K | 0.6% | — |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 141,200 | $691.9K | 0.5% | — |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 112,973 | $553.6K | 0.4% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 111,716 | $547.4K | 0.4% | ADD +35.6% |
| 16 | Point72 Asset Management, L.P. | 107,211 | $525.3K | 0.4% | — |
| 17 | COMMONWEALTH EQUITY SERVICES, LLC | 95,395 | $467.4K | 0.4% | ADD +25.4% |
| 18 | TWO SIGMA INVESTMENTS, LP | 93,500 | $458.1K | 0.3% | TRIM -27.1% |
| 19 | Nuveen, LLC | 93,158 | $456.5K | 0.3% | TRIM -55.9% |
| 20 | ALLIANCEBERNSTEIN L.P. | 69,110 | $390.5K | 0.3% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 8,234,299 | 10,987,017 | +33.4% | $53.8M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 6,422,018 | — | $31.5M | 2026-Q1 |
| ALPS ADVISORS INC | ADD | 45,079 | 59,629 | +32.3% | $292.2K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 134,031 | 58,229 | -56.6% | $285.3K | 2026-Q1 |
| Invesco Ltd. | ADD | 15,039 | 20,907 | +39.0% | $102.4K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 2,668 | 3,821 | +43.2% | $18.7K | 2026-Q1 |
| CWM, LLC | DOUBLED | 37 | 387 | +945.9% | $1.9K | 2026-Q1 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 5 | 154 | +2980.0% | $754.00 | 2026-Q1 |
| CWM, LLC | NEAR_EXIT | 196 | 37 | -81.1% | — | 2025-Q4 |
| MORGAN STANLEY | ADD | 75,941 | 134,031 | +76.5% | $757.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 136,116 | 99,200 | -27.1% | $560.5K | 2025-Q4 |
| Nuveen, LLC | TRIM | 209,662 | 92,482 | -55.9% | $522.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 26,311 | 73,899 | +180.9% | $417.5K | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 26,278 | 45,079 | +71.5% | $254.7K | 2025-Q4 |
| MetLife Investment Management, LLC | ADD | 15,488 | 19,443 | +25.5% | $109.9K | 2025-Q4 |
| Invesco Ltd. | ADD | 11,659 | 15,039 | +29.0% | $85.0K | 2025-Q4 |
| Russell Investments Group, Ltd. | ADD | 3,258 | 4,163 | +27.8% | $23.5K | 2025-Q4 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 19,638 | 25,814 | +31.4% | $146.00 | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | NEAR_EXIT | 64 | 5 | -92.2% | $28.00 | 2025-Q4 |
| Nuveen, LLC | DOUBLED | 92,482 | 209,662 | +126.7% | $1.1M | 2025-Q3 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 86,247 | 137,888 | +59.9% | $703.2K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 369,195 | 136,116 | -63.1% | $694.2K | 2025-Q3 |
| MARSHALL WACE, LLP | TRIM | 161,480 | 103,847 | -35.7% | $529.6K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 113,722 | 75,941 | -33.2% | $387.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 73,123 | 47,643 | -34.8% | $243.0K | 2025-Q3 |
3 unique insiders with 4 transactions. Net insider value: $3.0M ($3.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Manning Paul B | Director | AWARD | 4,618 | $4.11 | $19.0K |
| Mar 31, 2026 | PAPA JOSEPH C | Director | AWARD | 2,795 | $4.11 | $11.5K |
| Mar 31, 2026 | Loggia Nicoletta | Director | AWARD | 779 | $4.11 | $3.2K |
| Feb 23, 2026 | Manning Paul B | Director | BUY | 550,458 | $5.45 | $3.0M |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
4/10
Candel Therapeutics reported Q1 2026 results: net loss of $8.9M vs net income of $7.4M in Q1 2025, d
May 14, 2026
NEUTRAL
PRESS-RELEASE
5/10
Candel Therapeutics reported Q1 2026 EPS of -$0.54, a 65.6% miss vs consensus of -$0.33, with no rev
May 14, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K indicates a mater
Mar 12, 2026
BULLISH
8/10
Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN
Jun 2, 2026
BULLISH
8/10
Candel Therapeutics announced extended follow-up data from the phase 3 trial of aglatimagene (CAN-24
May 15, 2026
NEUTRAL
3/10
Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data
May 4, 2026
NEUTRAL
3/10
Candel Therapeutics entered into a commercialization agreement with EVERSANA to support the potentia
Apr 29, 2026
BULLISH
8/10
Candel Therapeutics released updated Phase 2a data for its immunotherapy aglatimagene (CAN-2409) in
Mar 17, 2026
MIXED
6/10
Candel Therapeutics reported Q4 and full-year 2025 financial results, highlighting a significant inc
Mar 12, 2026
Current analyst consensus: Strong Buy (87% buy). Based on 15 analysts: 4 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.29 mean target
+137.0% upside
Strong Buy (1.25)
$9.00 Low
$29.00 High
| Metric | Value |
|---|---|
| Current Price | $8.56 |
| Target Low | $9.00 |
| Target Mean | $20.29 |
| Target Median | $23.00 |
| Target High | $29.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.26 | $-0.26 | $-0.26 | -27.5% | — | — | $0.0B | 0.0% | 1 |
| Next Q 2026-09-30 |
$-0.26 | $-0.26 | $-0.26 | -14.9% | — | — | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.87 | $-1.11 | $-0.74 | 0.3% | -13.4% | — | $0.0B | 0.0% | 3 |
| Next FY 2027-12-31 |
$0.22 | $0.22 | $0.22 | 125.2% | +134.4% | 0↑ 1↓ | $0.1B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.260 | |
| 7d ago | $0.000 | -0.260 |
| 30d ago | $0.000 | -0.260 |
| 60d ago | $0.000 | -0.260 |
| 90d ago | $0.000 | -0.260 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 20, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 18, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| May 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% | |
| Apr 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 4 | 8 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
62°
Warm
Bearish
Neutral
Bullish
9 mentions
3 bullish
0 bearish
9 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 30, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 30, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 8, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 8, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 20, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
CADL stock next week!
▲ 1
💬 0
⚡ 0.5
CADL - CANDEL THERAUPETICS
▲ 1
💬 1
⚡ 0.5
CADL - CANDEL THERAUPETICS
▲ 1
💬 1
⚡ 0.5
Jun 2, 2026
fda
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
<p align="justify">NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-st
Jun 2, 2026
short_volume
Short Volume: CADL — 59.7% short (0.4M / 0.7M)
Short: 417,479 | Exempt: 1,211 | TRF Vol: 699,084 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
activist
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-st
May 15, 2026
fda
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
<p align="justify">NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 14, 2026
earnings
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
<p align="justify">NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 13, 2026
other
Candel Therapeutics to Present at Upcoming Investor Conferences
<p align="justify">NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-st
May 13, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-13
May 13, 2026
short_volume
Short Volume: CADL — 55.9% short (0.4M / 0.8M)
Short: 443,829 | Exempt: 6,807 | TRF Vol: 793,953 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: CADL — 59.1% short (1.0M / 1.7M)
Short: 1,016,312 | Exempt: 4,644 | TRF Vol: 1,720,323 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
CADL Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
short_volume
Short Volume: CADL — 61.6% short (0.8M / 1.3M)
Short: 808,906 | Exempt: 29,474 | TRF Vol: 1,312,834 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 4, 2026
fda
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
<p align="justify">NEEDHAM, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
May 1, 2026
other
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-sta
Apr 29, 2026
contract
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
<p align="left"><em>EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following pl